The U.S. government has taken a substantial step toward easing federal restrictions on marijuana by reclassifying the drug to a less stringent category. Acting Attorney General Todd Blanche signed an order on Thursday initiating the process of moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. This reclassification reflects a shift in federal policy that could simplify access to marijuana for medical purposes and create greater opportunities for the cannabis industry.

Since 1970, marijuana has been designated as a Schedule I substance, the most restrictive classification reserved for drugs deemed to have a high potential for abuse and no accepted medical use, alongside substances such as LSD and heroin. The new order downgrades marijuana to Schedule III, a category that includes drugs considered to have a moderate or low potential for physical and psychological dependence and recognized medical value. This designation allows marijuana products to be prescribed by licensed physicians and dispensed through pharmacies where legally permitted.

The order immediately applies to marijuana-containing products approved by the Food and Drug Administration (FDA), as well as those regulated under existing state medical marijuana programs. Acting Attorney General Blanche also announced plans for an expedited hearing aimed at considering a broader rescheduling of marijuana, potentially opening the door to wider legal access at the federal level.

This policy change represents the most significant federal adjustment to marijuana classification in decades, signaling a notable shift in the approach to cannabis regulation. Proponents argue that the move will facilitate research, expand medical treatment options, and provide clearer legal frameworks for businesses operating in the burgeoning cannabis market. However, some critics caution that rescheduling alone may not resolve all legal and regulatory challenges surrounding marijuana, and federal restrictions on recreational use remain intact.

The administration’s decision underscores evolving attitudes toward marijuana and could have far-reaching implications for the medical cannabis industry, law enforcement, and drug policy reform efforts at both state and federal levels.